April 5th 2022
Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.
March 29th 2022
Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.
A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.
March 22nd 2022
Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.
A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.
March 15th 2022
Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.
Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.
November 30th 2018
Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety signals with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) in endometrial cancer.
November 16th 2018
Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.
October 27th 2018
Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunogenicity in endometrial cancer.
August 10th 2018
Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the synergy between lenvatinib and pembrolizumab in the treatment of patients with endometrial cancer.
July 31st 2018
Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs and treatment challenges for patients with advanced endometrial cancer.